Julie A. Means‐Powell

Author

Vanderbilt University Medical Center

Also Known As

J. A. Means-Powell, Julie A Means-Powell, Julie A. Means-Powell, Julie A. Means‐Powell, Julie Ann Means-Powell

Publications

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Medical Center Vanderbilt University Roswell Park Comprehensive Cancer Center Arqule (United States)Tufts Medical Center

About

Julie A. Means‐Powell is an author at Vanderbilt University Medical Center specializing in cancer therapeutics, clinical trials, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	3	3	612
2	Medicine	3	3	612
3	Pharmacology	2	2	34
4	Hepatology	1	1	19
5	Immunology	1	1	15

Julie A. Means‐Powell

Publications

991

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation Joshua A. Bauer, A. Bapsi Chakravarthy, Jennifer M. Rosenbluth, Clinical Cancer Research	2010	186
A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer Xia Li, E. Brian Welch, Lori R. Arlinghaus, Physics in Medicine and Biology	2011	73
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors Igor Puzanov, Jeffrey A. Sosman, Armando Santoro, Investigational New Drugs	2014	56
Motion correction in diffusion‐weighted MRI of the breast at 3T Lori R. Arlinghaus, E. Brian Welch, A. Bapsi Chakravarthy, Journal of Magnetic Resonance Imaging	2011	32
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC) Julie A. Means‐Powell, Ingrid A. Mayer, Roohi Ismail‐Khan, Clinical Breast Cancer	2021	32
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. Robert E. Martell, Igor Puzanov, Wen Wee, Journal of Clinical Oncology PharmacotherapyMetronomic TherapyClinical TrialsArq 197Anti-cancer Agent	2012	19
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with <i>NRAS</i> wild-type or mutant melanoma from a phase I study. Julie A. Means‐Powell, Alex A. Adjei, Igor Puzanov, Journal of Clinical Oncology ImmunologySorafenib 400ImmunotherapeuticsImmunotherapyMutant Melanoma	2012	15

Page 1